Joe Rogan Experience #2079 - Brigham Buhler
Brigham Buhler (guest), Joe Rogan (host)
In this episode of The Joe Rogan Experience, featuring Brigham Buhler and Joe Rogan, Joe Rogan Experience #2079 - Brigham Buhler explores peptides, Big Pharma, and AI: Rebuilding Healthcare Outside Corrupt Systems Joe Rogan and Brigham Buhler argue that U.S. healthcare is structurally corrupted by Big Pharma, insurers, and their deep influence over agencies like the FDA and DOJ, leading to profit-driven decisions rather than patient outcomes.
Peptides, Big Pharma, and AI: Rebuilding Healthcare Outside Corrupt Systems
Joe Rogan and Brigham Buhler argue that U.S. healthcare is structurally corrupted by Big Pharma, insurers, and their deep influence over agencies like the FDA and DOJ, leading to profit-driven decisions rather than patient outcomes.
They focus on the recent FDA crackdown on peptides and compounding pharmacies, framing it as protection of patented pharmaceutical revenue rather than a response to real safety concerns, while noting similar patterns in opioids, insulin pricing, and HIV drugs.
Buhler outlines an alternative, cash-pay, preventative medicine model using comprehensive testing, peptides, red light therapy, stem cells, and other regenerative tools that traditional, insurance-based medicine largely ignores or actively suppresses.
He also describes how large language models and AI could power personalized, always-available, private health guidance—if kept outside insurer and pharma control—to scale high-end, data-driven care to the broader population.
Key Takeaways
Regulatory decisions often serve industry profits, not patient safety.
Buhler argues that the FDA’s move to classify many peptides as “dangerous” lacks safety data and aligns instead with pharma’s desire to patent and monopolize them, similar to historical examples in opioids, insulin pricing, and HIV drugs.
Get the full analysis with uListen AI
Insurance-backed healthcare is structurally designed to monetize chronic disease.
Through mechanisms like pharmacy benefit managers, tiered formularies, and opaque rebate schemes, insurers and PBMs profit from expensive, ongoing drug use rather than prevention, driving treatment choices away from root-cause solutions.
Get the full analysis with uListen AI
Comprehensive testing prior to prescribing could radically change mental and physical health outcomes.
Buhler advocates running detailed blood panels, genetic tests (e. ...
Get the full analysis with uListen AI
Peptides and stem-cell–based therapies can meaningfully accelerate healing when properly sourced and supervised.
He cites extensive anecdotal experience and emerging studies showing compounds like BPC-157, GLP-1 agonists, and umbilical-cord–derived cell products improving joint, tendon, and soft-tissue recovery—even in elite athletes—when made and administered under strict quality protocols.
Get the full analysis with uListen AI
Overregulation pushes patients into unsafe black markets rather than improving safety.
By choking off legitimate compounding pharmacies while leaving demand untouched, regulators risk repeating the opioid pattern: people will turn to unregulated, contaminated overseas products when supervised domestic options are removed.
Get the full analysis with uListen AI
AI and large language models could democratize high-level, personalized medical guidance.
Buhler describes building an avatar-based LLM that lives inside a closed, clinician-curated data environment, reading labs, MRIs, wearables, and notes to give patients 24/7, context-aware guidance and documentation, potentially scaling “Attia-level” care at lower cost.
Get the full analysis with uListen AI
Separating optimization and longevity care from insurance systems may be necessary to innovate.
Because insurers and regulators penalize extensive testing, “off-label” therapeutics, and ownership structures, Buhler argues that cash-pay clinics and independent labs are the only viable path to integrate peptides, stem cells, red light, and AI into proactive health strategies.
Get the full analysis with uListen AI
Notable Quotes
“What you're seeing is a symptom of a disease, and that disease is private industry and its influence on the federal government.”
— Brigham Buhler
“You cannot operate in that ecosystem and provide quality care. You can't.”
— Brigham Buhler, on the insurance-based model
“It's just bananas that it's that corrupt.”
— Joe Rogan
“These are Flintstone vitamins for grownups.”
— Brigham Buhler, describing peptides
“Are you gonna put your life in the hands of these fucking assholes that are here to extrapolate money from you and manage you into chronic disease?”
— Brigham Buhler
Questions Answered in This Episode
If peptides like BPC-157 have such strong safety and efficacy signals, what concrete process should exist to evaluate and approve them outside traditional pharma patent pathways?
Joe Rogan and Brigham Buhler argue that U. ...
Get the full analysis with uListen AI
How can patients and clinicians realistically push back against pharmacy benefit managers and opaque rebate systems that distort which drugs are covered and prioritized?
They focus on the recent FDA crackdown on peptides and compounding pharmacies, framing it as protection of patented pharmaceutical revenue rather than a response to real safety concerns, while noting similar patterns in opioids, insulin pricing, and HIV drugs.
Get the full analysis with uListen AI
What governance and ethical safeguards are needed to ensure AI-driven health assistants remain patient-centered and aren’t co-opted by insurers or pharma for risk-scoring and denial of care?
Buhler outlines an alternative, cash-pay, preventative medicine model using comprehensive testing, peptides, red light therapy, stem cells, and other regenerative tools that traditional, insurance-based medicine largely ignores or actively suppresses.
Get the full analysis with uListen AI
Where is the evidentiary line between promising anecdote and solid science for emerging therapies like stem cells, red light, and NAD/NMN—and who should be responsible for funding those studies?
He also describes how large language models and AI could power personalized, always-available, private health guidance—if kept outside insurer and pharma control—to scale high-end, data-driven care to the broader population.
Get the full analysis with uListen AI
If insurance-based primary care is so constrained, what practical steps can an average person take—on a limited budget—to start moving toward a more preventative, data-driven approach to their own health?
Get the full analysis with uListen AI
Transcript Preview
(drumbeats) Joe Rogan podcast, check it out. The Joe Rogan Experience.
Train by day, Joe Rogan podcast by night. All day. (instrumental music plays)
Hello, Joe. What's up, man?
(laughs)
We're back.
We're back. What's crackin'?
Same stuff, new day.
Yeah, sort of. Um, the war on peptides is going on right now.
It is.
It's interesting.
It's, uh, to, to explain it is, is gonna take a little bit of time, but I'd love to dig into it because I-
Yeah. Let's explain it, because there is no reason why they would be banning these things, other than for their own profit.
You got it. You got the gist of it. That's-
That's the only reason.
So-
There is no danger that these things are causing, there's no public health concern, there's no people dropping dead. But meanwhile, people are dropping dead from the ones that they have sanctioned.
Yeah, and so I- I like to tell people, "What you're seeing is a symptom of a disease," and the same thing we do in healthcare. We don't talk about the symptoms. We don't treat the s- we- we- we unfortunately do treat the symptom and not the root cause or the disease. And so, to diagnose what the real issue is, we've gotta dig a little deeper into the history and what's going on there. And, uh, it's a pretty insidious disease, and it's spread throughout all of the government. Uh, and that disease is private industry and its influence, uh, on the federal government and the decisions they make. Um, and we're gonna talk a little bit about large language models later in- in the future of what I think healthcare is. But one of the critiques of large language models is, it's only as good as the data you put in. And I would argue that humanity is no different. It is only as good as the data that you put in. And so, if the federal government and the FDA is going to allow an open door policy with big pharma, w- they're going to come to the conclusions, and decisions, and policies that benefit big pharma. And so, if we take a little walk through history, you'll see (laughs) time and time again how this has happened. So, I'm gonna jump way back first.
Okay.
If you're good with this.
Yes.
So, you go way back. Um, there was a small little company that reached out to the Third Reich and said, "Hey, we need 150 participants for our clinical trial." The Nazi regime shipped 150 healthy Jewish women to this, uh, this pharmaceutical company to test its products. Literally within six months, there's letters back to the Third Reich from this pharmaceutical company saying, "Thank you so much for your (laughs) cooperation. The women arrived in great health and working order. Unfortunately, none of them- none of them made it through the initial phases of our trial." They killed 150 women. "We kindly request that you send us another 150 women." That little company became Bayer, which is now a mega pharmaceutical company.
Install uListen to search the full transcript and get AI-powered insights
Get Full TranscriptGet more from every podcast
AI summaries, searchable transcripts, and fact-checking. Free forever.
Add to Chrome